◾ Type 2 diabetes mellitus (T2DM) is an important public health concern. By 2030, the number of people with diabetes is projected to reach over 350 million throughout the world, based on World Health Organization estimates 1 ◾ According to the Di@bet.es Study, 2 the prevalence of diabetes mellitus in Spain is 13.8%, with a total direct annual cost of 5,809 million Euros, which represents 8.2% of the total Spanish health expenditure 3 ◾ Canagliflozin (CANA) is a novel, oral antihyperglycemic agent (AHA), approved for the treatment of adults with T2DM, that inhibits sodium glucose co-transporter 2 (SGLT2) 4-17 -By inhibiting SGLT2, CANA reduces renal glucose reabsorption and increases urinary glucose excretion (UGE), thereby lowering blood glucose [18] [19] [20] ; this mechanism of action makes it complementary to other AHAs, including insulin, without inherent risk of hypoglycemia ◾ In Phase 3 studies, 5-17 CANA:
◾ The IMS CORE Diabetes Model (CDM; version 8.5+) was used to project the long-term clinical and cost outcomes associated with CANA based on the results of clinical trials. The CDM is a computer simulation model that was developed to simulate the long-term health outcomes and economic consequences of interventions in diabetes. More information on the CDM is available in previously published articles by Palmer et al 23, 24 and in the recent model validation 25 
Clinical Inputs
◾ Patient characteristics for the simulation exercise were obtained from a randomized controlled trial of CANA in dual therapy with background MET (DIA3006). 7 Treatment effects were sourced from DIA3006 and a Bayesian NMA of 26-week trials (HbA1c, body mass index [BMI] , and systolic BP [SBP] ). Where NMA data were not available, CANA and DAPA were assumed to have the same treatment effect, derived from the CANA clinical trial ( Table 1) ◾ HbA1c and SBP progressed for each patient according to the United Kingdom Prospective Diabetes Study (UKPDS) 68. 26 Lipids were modeled to progress according to the equations from the Framingham Heart Study. 27 BMI progression was assumed to be flat. The risk of cardiovascular complications was obtained using the UKPDS Outcomes Model 26 ◾ In these simulations, patients remained on their initial treatment until HbA1c exceeded 7.5%, at which point they switched to basal insulin (fixed dosage of 40 IU per day). It was assumed that when patients switched to insulin, MET was retained. The treatment effect on lipids and BMI was fully reversed (ie, an amount equal to the initial effect) when patients switched treatments ◾ The AEs related to glycemia-lowering drugs included in the model were severe and non-severe hypoglycemia, urinary tract infections, and genital mycotic infections (yeast) ◾ Non-diabetes-related mortality is included in the model using data from the National Institute of Statistics 28
Economic Inputs
◾ The annual costs of complications were derived from public sources and literature. If needed, these costs were inflated to 2013 prices using the official Consumer Price Index from the Organisation for Economic Cooperation and Development ◾ Unit costs for physician visits and laboratory and diagnostic tests came from official sources [29] [30] [31] ◾ Macrovascular and microvascular complication costs are shown in Table 2 ◾ Drug costs were obtained from Bot Plus in April 2015, with the exception of the CANA price, which was not publicly available at the time of the simulation. The mandatory discounts due to "Real Decreto-ley 8/2010, de 20 de mayo" were applied when needed 32
◾ Utilities were assigned to events and health states ( Table 3 ). The main source for utilities was the Spanish National Survey. 40 In the absence of Spain-specific data, disutilities reported in Beaudet et al were applied to the Spanish-specific utility associated with T2DM without complications 41 ◾ The time horizon used for the economic evaluation was 40 years to approximate a lifelong time horizon, and an annual discount rate of 3% was applied for costs and for health effects
Sensitivity Analyses
◾ Several sensitivity analyses were performed in order to test the robustness of the results. Time horizon and price sensitivity analyses are shown below
RESULTS
◾ CANA 100 and 300 mg dominated DAPA 10 mg in dual therapy. The savings were €1,084 and €615, respectively, with incremental quality-adjusted life-year (QALY) gains of 0.061 and 0.084, respectively ( Table 4) ◾ Figure 1 shows the cost-effectiveness planes for both comparisons. The majority of points lie in the eastern quadrants, suggesting that CANA is more effective than DAPA ◾ One-way sensitivity analysis revealed that the time horizon is a strong driver of cost-effectiveness. When a time horizon of 5 years is used, CANA 100 mg remains dominant, but the incremental cost-utility ratio for CANA 300 mg increases to a level of €7,770, still below the willingness-to-pay threshold in Spain ◾ In the one-way sensitivity analysis, the price of DAPA 10 mg was set equal to that of CANA 100 mg; results show that CANA 100 mg is dominant under this assumption ( Table 5) DISCUSSION ◾ As with any modeling study in T2DM, results should be interpreted appropriately, as treatment effects and AE rates were taken from short-term studies and extrapolated 
CONCLUSION
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